Inozyme Pharma Stock Market Value
| INZY Stock | USD 2.81 0.12 4.46% |
| Symbol | Inozyme |
Inozyme Pharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme Pharma. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Return On Assets (0.36) | Return On Equity (0.79) |
The market value of Inozyme Pharma is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme Pharma's value that differs from its market value or its book value, called intrinsic value, which is Inozyme Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme Pharma's market value can be influenced by many factors that don't directly affect Inozyme Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Inozyme Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Inozyme Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Inozyme Pharma.
| 12/06/2022 |
| 11/25/2024 |
If you would invest 0.00 in Inozyme Pharma on December 6, 2022 and sell it all today you would earn a total of 0.00 from holding Inozyme Pharma or generate 0.0% return on investment in Inozyme Pharma over 720 days. Inozyme Pharma is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal... More
Inozyme Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Inozyme Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Inozyme Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.27) | |||
| Maximum Drawdown | 16.62 | |||
| Value At Risk | (7.92) | |||
| Potential Upside | 5.68 |
Inozyme Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inozyme Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Inozyme Pharma's standard deviation. In reality, there are many statistical measures that can use Inozyme Pharma historical prices to predict the future Inozyme Pharma's volatility.| Risk Adjusted Performance | (0.17) | |||
| Jensen Alpha | (1.09) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | (0.42) |
Inozyme Pharma Backtested Returns
Inozyme Pharma holds Efficiency (Sharpe) Ratio of -0.27, which attests that the entity had a -0.27% return per unit of risk over the last 3 months. Inozyme Pharma exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Inozyme Pharma's Standard Deviation of 3.61, risk adjusted performance of (0.17), and Market Risk Adjusted Performance of (0.41) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.01, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inozyme Pharma will likely underperform. At this point, Inozyme Pharma has a negative expected return of -0.98%. Please make sure to check out Inozyme Pharma's value at risk, rate of daily change, relative strength index, as well as the relationship between the kurtosis and market facilitation index , to decide if Inozyme Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.15 |
Insignificant predictability
Inozyme Pharma has insignificant predictability. Overlapping area represents the amount of predictability between Inozyme Pharma time series from 6th of December 2022 to 1st of December 2023 and 1st of December 2023 to 25th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Inozyme Pharma price movement. The serial correlation of 0.15 indicates that less than 15.0% of current Inozyme Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.15 | |
| Spearman Rank Test | 0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.67 |
Inozyme Pharma lagged returns against current returns
Autocorrelation, which is Inozyme Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Inozyme Pharma's stock expected returns. We can calculate the autocorrelation of Inozyme Pharma returns to help us make a trade decision. For example, suppose you find that Inozyme Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Inozyme Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Inozyme Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Inozyme Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Inozyme Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
Inozyme Pharma Lagged Returns
When evaluating Inozyme Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Inozyme Pharma stock have on its future price. Inozyme Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Inozyme Pharma autocorrelation shows the relationship between Inozyme Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Inozyme Pharma.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.